| Purpose:The purpose of this study was to observe the effect of Liraglutide o n body fat rate(BFR)and atherogenic index of plasma(AIP)in hypertensive p atients with diabetes mellitus,and to provide more evidence for its clinical appli cation.Materials and Methods: 75 patients with primary hypertension combined with diabetes mellitus who were admitted to the Second Hospital of Dalian Medical University from September 2021 to September 2022 were selected.Based on the selection and exclusion criteria,they were randomly allocated to two groups:38cases of these patients were set up as the control group and given the usual reg imen of blood glucose control,lipid control and blood pressure control,and thos e who applied liraglutide on top of the treatment regimen of the control group were set as the observation group(37 cases).The information collection for the selected subjects consisted of gender,age,hypertensive history,medical history,medication history,tobacco history,alcohol history,systolic blood pressure(SBP) and diastolic blood pressure(DBP).Fasting venous blood was collected in the early morning to detect fasting blood glucose(FPG),glycosylated hemoglobin(H b A1c),total cholesterol(TC),triglyceride(TG),high-density lipoprotein cholesterol (HDL-C),low-density lipoprotein cholesterol(LDL-C),and calculate the AIP ba sed on TG and HDL-C.A body composition analyser was used to measure weigh t(W),body mass index(BMI),body fat mass,body fat rate(BFR),skeletal mu scle mass,waist-hip ratio(WHR),visceral fat area(VFA).All Patients were treate d for 12 weeks,and after 12 weeks,glucose and lipid metabolism indicators wer e statistically analysed in the 2 groupsResutls:1.Comparison of general baseline data,glucose metabolism,lipid metabolism and body fat metabolism between the two groups: The two groups’ general baseline data,glucose metabolism,lipid metabolism and body fat metabolism were shown to be comparable,not significantly different from each other before treatment(P>0.05).2.Variation in the glucose metabolism levels of patients in the observation and control groups: In the control group,FPG and Hb A1 c levels decreased compared with those before treatment,but the difference was not statistically significant(P>0.05);In the observation group,FPG and Hb A1 c levels decreased significantly compared with those before treatment,and the difference was significant(P<0.01).After 12 weeks of therapy,FPG [6.32(5.96,8.11)mmol/L] and Hb A1 c [(7.40±1.11)%] levels in the observation group were reduced more obviously than FPG [7.39(6.46,10.45)mmol/L]and Hb A1 c [(8.12±1.42)%] levels in the control group,and the difference was statistically significant(p<0.05);after 12 weeks of treatment,the extent of the decline in FPG and Hb A1 c levels in the observation group [1.33(-0.05,3.32)mmol/L],[(1.03±1.61)%] was even more significant than that in the control group [(0.57(-0.19,2.47)mmol/L],[(0.33±1.24)%] were more significant and the difference was statistically significant(P<0.05).3.Changes in blood pressure levels in the two groups: The SBP level in the control group declined significantly in comparison with the pre-treatment level,and the result was statistically significant(P<0.05),however,the DBP level in the control group showed a decreasing trend in comparison with the pre-treatment level,but there was no statistical difference(P>0.05);The SBP and DBP levels in the observation group were significantly lower than those before treatment,and the difference was statistically significant(P<0.05).After 12 weeks of treatment,the decrease in SBP level[(127.95±13.98)mm Hg] in the observation group was found to be significant(P<0.05)compared to the SBP [(137.68±20.99)mm Hg] level in the control group,but the difference in DBP level in the observation group was not statistically significant(P>0.05),although it was also reduced compared to the control group.After treatment,the decrease in SBP and DBP levels in the observation group was statistically significant compared to the control group(P<0.05).4.Changes in lipid metabolism levels in the two groups: TG,HDL-C and AIP levels in the control group had a trend of decrease compared to the pre-treatment level,but the difference was not considered statistically significant(p>0.05),while TC and LDL-C levels in the control group all increased to different degrees compared with treatment,with no statistical difference;the levels of TC,TG,LDL-C and AIP were all significantly lower than those before treatment,with statistical differences(P<0.05),while the HDH-C water in the observation group was significantly higher compared with that before treatment,with statistically significant differences(P<0.05).After 12 weeks of treatment,the TC [(3.48(3.21,4.47)mmol/L],TG [1.50(1.20,1.59)mmol/L],LDL-C [1.93(1.55,2.56)mmol/L] and AIP(0.08±0.17)levels in the observation group compared with TC[4.57(3.64,(5.50)mmol/L],TG [1.72(1.18,2.86)mmol/L],LDL-C[2.62(1.93,3.52)mmol/L] and AIP(0.22±0.25)levels in the control group were significantly lower,The difference was significant statistically(P < 0.05).After therapy,the reductions in TC,TG,LDL-C,and AIP were more significant in the control group than in the control group(P < 0.05).5.Changes in body fat indexes in the two groups:In the control group,only VFA levels showed a statistically significant decrease in body fat indicators compared to pre-treatment(p < 0.05);W,body fat mass,BFR,BMI,WHR and VFA levels were all reduced compared to treatment in the observation group,with meaningful reduction(p<0.01);After 12 weeks of treatment,the body fat rate of the observation group decreased more significantly than that of the control group(p<0.05);However,following treatment,in observation group,W[4.00(2.80,4.70)kg],body fat(3.15±1.37)kg,BFR(2.60±1.42)%,BMI[1.36(0.98,1.77)kg/m2],WHR[0.01(0.00,0.02)],VFA[2.30(0.85,3.10)cm2] levels decreased significantly compared with W[0.65(-0.73,1.10)kg],body fat(0.09±1.25)kg,BFR(-0.01±1.21)%,BMI[0.25(-0.27,0.36)kg/m2],WHR[0.00(0.00,0).01)),VFA[1.00(-0.13,2.08)cm2] levels decreased in the control group,and the difference was statistically significant(p<0.05).Conclusions:1.Liraglutide can effectively reduce FPG,Hb A1 c,SBP,DBP,TC,TG,LDL-C,W,body fat mass,BMI,WHR,and further reduce the levels of VFA,FBR and AIP in patients with hypertension and diabetes mellitus on the basis of conventional hypoglycemic,lipid lowering and antihypertensive treatment.2.Liraglutide may achieve cardiovascular benefits by improving AIP,BFR,and VFA levels in patients with essential hypertension and diabetes and reducing the risk of atherosclerosis. |
PDF Full Text Request